Home / Top News / Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer Gene therapy development expert Petra Kaufmann, M.D.,
joins as chief medical officer –
WALTHAM, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced the completion of its leadership team. Collectively, the executives represent a diverse team of proven leaders in gene therapy who have successfully developed novel platforms and translated the
All US Middle and High School Students are Welcome to Enter
The 2021 G4C Student Challenge Competition has been officially announced. This annual game design competition is designed to act as a bridge between students’ love of video games and civic engagement, encouraging them to make games about issues that affect their communities. From February 1 to April 1, middle and high school students across the US will be able to submit their own, original social impact games. Winners will receive prizes for “technology, video games, thematic- and games industry-related opportunities” and Grand Prize winners will get a $1,000 scholarship provided by Take-Two Interactive.
New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countries without the n
E-Mail
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation.
The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021.
The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic.
Preliminary tests of the vaccines stability and potency at different temperatures revealed that AAVCOVID candidates remained potent and effective when stored at room temperature for up to one month. This room temperature stability and the fact AAVCOVID vaccines do not require cold-chain freezer storage, could enable this AAV-based platform to develop a vaccine for COVID-19 and other diseases for developing countries without the necessary cooling infrastructure some vaccines require.
by Jim Shamp, NCBiotech writer January 7, 2021 .
RESEARCH TRIANGLE PARK – California gene therapy innovator Adverum Biotechnologies announced plans today to invest $83 million to establish a manufacturing site in Durham that will employ 202 people at an average salary of $93,762 when fully operational.
It’s the latest in a string of cell- and gene-therapy companies drawn to the Triangle for its trained workforce, academic prowess and attractive business, social and meteorological climate.
The publicly held company, (Nasdaq: ADVM), is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum’s lead product candidate, ADVM-022, is a one-time injection into the eye to treat conditions such as wet age-related macular degeneration and diabetic macular edema.